Morgan Stanley’s Augmedix, Inc. Common Stock AUGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-105,401
| Closed | -$248K | – | 8231 |
|
|
2024
Q3 | $248K | Buy |
105,401
+63,841
| +154% | +$129K | ﹤0.01% | 5672 |
|
|
2024
Q2 | $36.6K | Sell |
41,560
-5,991
| -13% | -$12.4K | ﹤0.01% | 6263 |
|
|
2024
Q1 | $194K | Buy |
47,551
+15,469
| +48% | +$69.2K | ﹤0.01% | 5750 |
|
|
2023
Q4 | $188K | Buy |
32,082
+31,082
| +3,108% | +$164K | ﹤0.01% | 5971 |
|
|
2023
Q3 | $5.15K | Hold |
1,000
| – | – | ﹤0.01% | 6913 |
|
|
2023
Q2 | $4.81K | Hold |
1,000
| – | – | ﹤0.01% | 6994 |
|
|
2023
Q1 | $1.74K | Hold |
1,000
| – | – | ﹤0.01% | 7266 |
|
|
2022
Q4 | $1.56K | Hold |
1,000
| – | – | ﹤0.01% | 7410 |
|
|
2022
Q3 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 7625 |
|
|
2022
Q2 | $2K | Hold |
1,000
| – | – | ﹤0.01% | 7618 |
|
|
2022
Q1 | $3K | Sell |
1,000
-64
| -6% | -$174 | ﹤0.01% | 7699 |
|
|
2021
Q4 | $3K | Buy |
+1,064
| New | +$3.86K | ﹤0.01% | 7756 |
|
Morgan Stanley's AUGX Position: Q4 2024 in Review
Morgan Stanley sold out of Augmedix, Inc. Common Stock (AUGX) in Q4 2024, closing a stake of 105,401 shares — an estimated $248K sold.
Morgan Stanley first reported a position in AUGX in Q4 2021 and held it in 12 quarters. The position peaked at $248K in Q3 2024. 0 funds tracked by Wall St. Rank hold AUGX as of Q4 2024.
- Morgan Stanley reported no remaining Augmedix, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 105,401 Augmedix, Inc. Common Stock shares in Q4 2024, an estimated $248K.
- Morgan Stanley first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 12 quarters.
- Morgan Stanley's Augmedix, Inc. Common Stock position peaked at $248K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.